J Korean Med Assoc.  2006 Feb;49(2):134-141. 10.5124/jkma.2006.49.2.134.

Pharmacotherapeutic Interventions to Maintaining Abstinence in Alcoholism

• Namkoong K

• KMID: 2184661
• DOI: http://doi.org/10.5124/jkma.2006.49.2.134

Abstract

Alcoholism, a major public health problem throughout the world, causes an enormous damage to health and quality of life and undermines the well being of families and society. It is associated with liver disease, cancer, cardiovascular problems, accidental deaths, suicides, and homicides. Over the last 20 years, a significant progress has been made in the pharmacological treatment of alcoholism owing to the better understanding of the neurobiological substrates of alcohol dependence, including adaptive changes in amino acid neurotransmitter systems, stimulation of dopamine and opioid peptide systems, and, possibly, changes in serotonergic activity. Disulfiram, naltrexone and acamprosate are the only pharmacological agents currently approved for the management of alcohol dependence. Data from studies of ondansetron and topiramate in alcohol dependence are somewhat promising, but it appears that the evidence of efficacy of these drugs in large controlled clinical trials are still lacking. Trials with SSRIs and some antipsychotics have shown disappointing results. Because the biological basis of alcohol dependence appears to be multifactorial, the future of management of alcoholism would involve combination therapy, using drugs acting on different neuronal pathways, such as acamprosate and naltrexone. Pharmacotherapy should be used in association with appropriate psychosocial support and specific treatment for any underlying psychiatric comorbidities.

Keyword

Alcohol Dependence; Pharmacotherapy

MeSH Terms

Alcoholism*
Antipsychotic Agents
Comorbidity
Disulfiram
Dopamine
Drug Therapy
Homicide
Humans
Liver Diseases
Naltrexone
Neurons
Neurotransmitter Agents
Ondansetron
Opioid Peptides
Public Health
Quality of Life
Suicide
Antipsychotic Agents
Disulfiram
Dopamine
Naltrexone
Neurotransmitter Agents
Ondansetron
Opioid Peptides

Reference

1. Volpicelli JR, Alterman AI, Hayashida M. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992. 49:876–880.

2. Volpicelli JR. Alcohol abuse and alcoholism: an overview. J Clin Psychiatry. 2001. 62:Suppl 20. 4–10.

3. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction. 2004. 99:21–24.

4. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism: a veterans administration cooperative study. JAMA. 1986. 256:1449–1455.

5. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: Van evidence-based risk-benefits assessment. Eur Neuropsychopharmacol. 2003. 13:469–475.

6. Durbin P, Hulot T, Chabac S. Soyka M, editor. Pharmacodynamics and pharmacokinetics of acamprosate : An overview. Acamprosate in Relapse Prevention of Alcoholism. 1995. Berlin: Springer-Verlag;47–64.

7. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry. 1996. 53:673–680.

8. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol: Alcohol and Alcoholism. Alcohol Alcohol. 1995. 30:239–247.

9. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry. 1997. 171:73–75.

10. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom multicentre acamprosate study (UKMAS): a 6 month prospective study of acamprosate vs placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000. 35:176–187.

11. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Korean Acamprosate Clinical Trial Investigators. Acamprosate in Korean alcohol dependent patients: a multi-center, randomized, double-blind, placebo-ontrolled study. Alcohol. Alcohol Alcohol. 2003. 38:135–134.

12. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone. J Clin Psychiatry. 1984. 45:15–19.

13. Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry. 1995. 56:Suppl 7. 24–29.

14. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Veterans Affairs Naltrexone Cooperative Study 425 Group. naltrexone in the treatment of alcohol dependence[see comment]. N Engl J Med. 2001. 345:1734–1739. Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial.

15. Croop RS, Labriola DF, Wroblewski JM, Nibbelink DW. A multicenter safety study of naltrexone as adjunctive pharmacotherapy for individuals with alcoholism. Presented at annual meeting of the American Psychiatric association. 1995. 20–25.

16. Verebey K, Volavska J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism, and effect after acute and chronic dosing. Clinical Pharmacology and Therapeutics. 1976. 20:315–328.

17. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. Journal of Clinical Psychopharmacology. 2001. 21:632–634.

18. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000. 284:963–971.

19. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003. 361:1677–1685.

20. Johnson BA, Swift RM, Ait DN, DiClemente CC, Javors MA, Malcolm RJ. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res. 2004. 28:295–301.

21. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997. 54:700–705.

22. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000. 24:1041–1049.

23. Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction. 1995. 90:87–99.

24. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner R, Brown J, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry. 1994. 51:720–731.

25. Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry. 1994. 165:515–523.

26. Guardia J, Segura L, Gonzalvo B, Iglesias L, Roncero C, Cardus M, et al. A double-lind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004. 28:736–745.

27. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000. 26:441–449.